Cue Biopharma
NASDAQ: CUEBoston, US · Founded 2014 · Delaware corporation · 1 known investors
Cue Biopharma is a clinical-stage biopharmaceutical company developing precision immuno-engineered therapies aimed at functional cures for allergic and autoimmune diseases. Its lead programs include CUE-221, an anti-IgE candidate in Phase 2 for allergic diseases, and CUE-401, a bifunctional IL-2/TGF-β therapy for autoimmune and inflammatory conditions.
Founders & leadership
DB
Daniel BakerExecutive
CS
Colin SandercockExecutive
DB
Dominic BorieChief Medical Officer and Head of Research and Development
SR
Sumita RayExecutive
MM
Michael MeluzioExecutive
RC
Rodolfo ChaparroVice President, Head of Immunology
RS
Ronald Seidel IIIExecutive Vice President, Head of Research and Development
GS
Gary SchumanChief Financial Officer
CG
Cameron GrayChief Executive Officer and President
JM
James M. AhlersCFO
AD
Anthony DiGiandomenicoNamed on SEC filing
Board
PV
Patrick VerheyenBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$136.4M disclosed across 5 of 6 rounds · 2015–2026
▶$50MraisedJul 2026 · 4 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shao-Lee LinExecutive Officer, Director
- Dominic BorieExecutive Officer
- Sumita RayExecutive Officer
- Daniel CamardoDirector
- Pamela GarzoneDirector
- Viola MeehanDirector
- Pasha SarrafDirector
- Michael MeluzioExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedMay 2026 · 118 investors · BiotechnologyRule 506(b)
▶$30MraisedMay 2026 · 118 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick VerheyenDirector
- Daniel BakerExecutive Officer
- Peter KienerDirector
- Frank MorichDirector
- Pamela D. GarzoneDirector
- Colin SandercockExecutive Officer
- Jill M. BroadfootDirector
- Shao-Lee LinExecutive Officer, Director
- Pasha SarrafDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Newbridge Securities Corporation
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedNov 2022 · 64 investors · BiotechnologyRule 506(b)
▶$30MraisedNov 2022 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tamar HowsonDirector
- Daniel R. PasseriExecutive Officer, Director
- Aaron FletcherDirector
- Peter A. KienerDirector
- Kerri-Ann MillarExecutive Officer
- Anish SuriExecutive Officer
- Frank MorichDirector
- Frederick DriscollDirector
- Patricia NasshornExecutive Officer
- Colin G. SandercockExecutive Officer
- Ken PientaExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Public Ventures, LLC, Piper Sandler & Co.
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.4MraisedDec 2016 · 133 investors · BiotechnologyRule 506(b)
▶$16.4MraisedDec 2016 · 133 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD SEIDEL IIIExecutive Officer
- ANTHONY DIGIANDOMENICODirector
- CAMERON GRAYDirector
- GARY SCHUMANExecutive Officer
- STEVEN MCKNIGHTDirector
- AMY WANGDirector
- RODOLFO CHAPARROExecutive Officer
- DANIEL PASSERIExecutive Officer, Director
- CHRISTOPHER MARLETTDirector
- PETER KIENERDirector
- BARRY SIMONDirector
- Offering amount
- $16.4M
- Amount sold
- $16.4M
- Sales commissions
- $1.3M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10MraisedJun 2015 · 121 investors · BiotechnologyRule 506(b)
▶$10MraisedJun 2015 · 121 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary SchumanExecutive Officer, Director
- Christopher MarlettDirector
- Steven AlmoExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Anthony DiGiandomenicoDirector
- Cameron GrayExecutive Officer, Director
- Amy WangExecutive Officer, Director
- Rodolfo ChaparroExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MofferedJun 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1MofferedJun 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodolfo ChaparroExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Christopher MarlettDirector
- Gary SchumanExecutive Officer, Director
- Cameron GrayExecutive Officer, Director
- Anthony DiGiandomenicoDirector
- Amy WangExecutive Officer, Director
- Steven AlmoExecutive Officer
- Offering amount
- $1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapKite Pharma20 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
IQVIA15 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Cue Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - BioSpacebiospace.com · Aug 2026
Cue Biopharma Appoints Veteran James Ahlers as CFO - TipRanks.comtipranks.com · Aug 2026Frequently asked questions
- What does Cue Biopharma do?
- Cue Biopharma is a clinical-stage biopharmaceutical company developing precision immuno-engineered therapies aimed at functional cures for allergic and autoimmune diseases. Its lead programs include CUE-221, an anti-IgE candidate in Phase 2 for allergic diseases, and CUE-401, a bifunctional IL-2/TGF-β therapy for autoimmune and inflammatory conditions.
- Who are Cue Biopharma's investors?
- Cue Biopharma's investors include Bios Partners.
- How much funding has Cue Biopharma raised?
- Cue Biopharma has disclosed $136.4M raised across 5 of its 6 known rounds.
- Where is Cue Biopharma headquartered?
- Cue Biopharma is headquartered in Boston, US.